secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProtoKinetix, Inc. (PKTX)
CIK:        0001128189
Form:       8-K
Filed at:   2026-06-17T21:28:41+00:00
Accession:  0001079973-26-000855
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProtoKinetix appoints new President, forms SightPath Biotech, patents valued at $253M
--------------------------------------------------------------------------------

- Director McDonough resigned March 31; June 17: Jones, Lamp, Brunt appointed directors, Brunt as President.
- Formed SightPath Biotech LLC for dry-eye drug PKX-001; patent valuation ~$253M per IQVIA & Benoit & Cote studies.
- Late filings: 2025 10-K (Mar 31) and Q1 2026 10-Q (May 15); company still working to complete.
- Repriced 61.19M options and 6M warrants from $0.028 to $0.01, extended expiry to Dec 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/pktx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-000855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer